A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion

被引:10
作者
Fichter, Christiane Daniela [1 ,2 ,3 ]
Przypadlo, Camilla Maria [1 ,2 ]
Buck, Achim [4 ]
Herbener, Nicola [1 ,2 ]
Riedel, Bianca [1 ,2 ]
Schaefer, Luisa [1 ,2 ]
Nakagawa, Hiroshi [5 ]
Walch, Axel [4 ]
Reinheckel, Thomas [2 ,6 ,7 ,8 ,9 ,10 ]
Werner, Martin [1 ,2 ,7 ,9 ,10 ]
Lassmann, Silke [1 ,2 ,3 ,7 ,8 ,9 ,10 ]
机构
[1] Univ Freiburg, Inst Surg Pathol, Med Ctr, Breisacherstr 115a, D-79106 Freiburg, Germany
[2] Univ Freiburg, Fac Med, Freiburg, Germany
[3] Univ Freiburg, Fac Biol, Freiburg, Germany
[4] Helmholtz Zentrum Munchen, Res Unit Analyt Pathol, Neuherberg, Germany
[5] Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA
[6] Univ Freiburg, Inst Mol Med & Cell Res, Freiburg, Germany
[7] Univ Freiburg, Comprehens Canc Ctr Freiburg, Med Ctr, Freiburg, Germany
[8] Univ Freiburg, BIOSS Ctr Biol Signalling Studies, Freiburg, Germany
[9] German Canc Consortium DKTK, Partner Site Freiburg, Heidelberg, Germany
[10] German Canc Res Ctr, Heidelberg, Germany
关键词
oesophageal cancer; ErbB homodimers; ErbB heterodimers; non-apoptotic blebbing; cell migration; cell invasion; HER-2/NEU GENE AMPLIFICATION; PROTEIN OVEREXPRESSION; IN-VITRO; CANCER; EXPRESSION; MIGRATION; EGFR; ASSOCIATION; CARCINOMA; P63;
D O I
10.1002/path.4987
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Oesophageal squamous cell carcinomas and oesophageal adenocarcinomas show distinct patterns of ErbB expression and dimers. The functional effects of specific ErbB homodimers or heterodimers on oesophageal (cancer) cell behaviour, particularly invasion during early carcinogenesis, remain unknown. Here, a new cellular model system for controlled activation of epidermal growth factor receptor (EGFR) or human epidermal growth factor receptor 2 (HER2) and EGFR-HER2 or HER2-human epidermal growth factor receptor 3 (HER3) homodimers and heterodimers was studied in non-neoplastic squamous oesophageal epithelial Het-1A cells. EGFR, HER2 and HER3 intracellular domains (ICDs) were fused to dimerization domains (DmrA/DmrA and DmrC), and transduced into Het-1A cells lacking ErbB expression. Dimerization of EGFR, HER2 or EGFR-HER2 and HER2-HER3 ICDs was induced by synthetic ligands (A/A or A/C dimerizers). This was accompanied by phosphorylation of the respective EGFR, HER2 and HER3 ICDs and activation of distinct downstream signalling pathways, such as phospholipase C1, Akt, STAT and Src family kinases. Phenotypically, ErbB dimers caused cell rounding and non-apoptotic blebbing, specifically in EGFR-HER2 and HER2-HER3 heterodimer cells. In a Transwell assay, cell migration velocity was elevated in HER2 dimer cells as compared with empty vector cells. In addition, HER2 dimer cells showed in increased cell invasion, reaching significance for induced HER2-HER3 heterodimers (P=0.015). Importantly, in three-dimensional organotypic cultures, empty vector cells grew as a superficial cell layer, resembling oesophageal squamous epithelium. In contrast, induced HER2 homodimer cells were highly invasive into the matrix and formed cell clusters. This was associated with partial loss of cytokeratin 7 (when HER2 homodimers were modelled) and p63 (when EGFR-HER2 heterodimers were modelled), which suggests a change or loss of squamous cell differentiation. Controlled activation of specific EGFR, HER2 and HER3 homodimers and heterodimers caused oesophageal squamous epithelial cell migration and/or invasion, especially in a three-dimensional microenvironment, thereby functionally identifying ErbB homodimers and heterodimers as important drivers of oesophageal carcinogenesis. Copyright (c) 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:481 / 495
页数:15
相关论文
共 50 条
  • [31] Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors
    Niikura, Naoki
    Liu, Jun
    Hayashi, Naoki
    Mittendorf, Elizabeth A.
    Gong, Yun
    Palla, Shana L.
    Tokuda, Yutaka
    Gonzalez-Angulo, Ana M.
    Hortobagyi, Gabriel N.
    Ueno, Naoto T.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) : 593 - 599
  • [32] Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer
    Creedon, Helen
    Byron, Adam
    Main, Joanna
    Hayward, Larry
    Klinowska, Teresa
    Brunton, Valerie G.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2014, 42 : 822 - 830
  • [33] Epidermal growth factor receptor function in the human urothelium
    Wasen, C.
    Ekstrand, M.
    Levin, M.
    Giglio, D.
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2018, 50 (04) : 647 - 656
  • [34] Expression of Nucleostemin, epidermal growth factor and epidermal growth factor receptor in human esophageal squamous cell carcinoma tissues
    Zhang, Gongyuan
    Zhang, Qiao
    Zhang, Qinxian
    Yin, Lei
    Li, Shenglei
    Cheng, Kuisheng
    Zhang, Yunhan
    Xu, Honghui
    Wu, Weidong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (04) : 587 - 594
  • [35] Dual Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Inhibition in Squamous Cell Carcinoma of the Head and Neck; Is the Jury Still Out?
    Saba, Nabil F.
    Wong, Stuart J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (17) : 2072 - +
  • [36] Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3
    Hester A. Doyle
    Raymond A. Koski
    Nathalie Bonafé
    Ross A. Bruck
    Stephanie M. Tagliatela
    Renelle J. Gee
    Mark J. Mamula
    Cancer Immunology, Immunotherapy, 2018, 67 : 1559 - 1569
  • [37] Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3
    Doyle, Hester A.
    Koski, Raymond A.
    Bonafe, Nathalie
    Bruck, Ross A.
    Tagliatela, Stephanie M.
    Gee, Renelle J.
    Mamula, Mark J.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (10) : 1559 - 1569
  • [38] Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
    Ahmed, Nabil
    Brawley, Vita S.
    Hegde, Meenakshi
    Robertson, Catherine
    Ghazi, Alexia
    Gerken, Claudia
    Liu, Enli
    Dakhova, Olga
    Ashoori, Aidin
    Corder, Amanda
    Gray, Tara
    Wu, Meng-Fen
    Liu, Hao
    Hicks, John
    Rainusso, Nino
    Dotti, Gianpietro
    Mei, Zhuyong
    Grilley, Bambi
    Gee, Adrian
    Rooney, Cliona M.
    Brenner, Malcolm K.
    Heslop, Helen E.
    Wels, Winfried S.
    Wang, Lisa L.
    Anderson, Peter
    Gottschalk, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15) : 1688 - +
  • [39] Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer
    Finn, Richard S.
    Press, Michael F.
    Dering, Judy
    Arbushites, Michael
    Koehler, Maria
    Oliva, Cristina
    Williams, Lisa S.
    Di Leo, Angelo
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (24) : 3908 - 3915
  • [40] Harnessing molecular probes for imaging of human epidermal growth factor receptor (HER) family
    Li, Na
    Chen, Shengxi
    Cai, Xiaoqing
    BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 113